NGEN NervGen Pharma Corp.
Price Chart
Executive Summary
NervGen Pharma reported full-year 2025 financial results and provided clinical updates, including completion of its End-of-Phase 2 meeting with the FDA and plans to initiate a Phase 3 trial in chronic tetraplegia in mid-2026. While R&D expenses decreased, net loss nearly doubled to $44.1 million due to non-cash charges, and cash increased to $22.1 million. The company expects to release additional clinical data in 2Q 2026.
Key Financial Metrics
Actionable Insight
Traders should monitor the upcoming regulatory update and biomechanical gait data in 2Q 2026, which could validate the neural recovery mechanism of NVG-291. Despite a wider net loss, the improved cash position supports continued development, but future dilution risk remains if additional funding is needed.
Key Facts
- Completed End-of-Phase 2 FDA meeting; regulatory update expected in early 2Q 2026
- On track to initiate Phase 3 study in chronic tetraplegia in mid-2026
- Cash and investments increased to $22.1 million as of December 31, 2025, from $17.3 million in 2024
- R&D expenses decreased to $13.9 million in 2025 from $15.8 million in 2024
- Net loss widened to $44.1 million in 2025 from $24.3 million in 2024, driven by $24.8 million in non-cash expenses
- Biomechanical gait data from CONNECT SCI study expected in 2Q 2026
Financial Impact
Net loss increased by 81% YoY to $44.1M, primarily due to non-cash expenses; cash position improved by $4.8M to $22.1M
Risk Factors
- Net loss nearly doubled due to non-cash charges, raising concerns about sustainability
- Clinical timelines are dependent on regulatory feedback and additional funding
- No revenue-generating products; company remains in clinical development stage
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265362 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
13d ago
|
6-K
| $2.00 $1.91 | ▲ +4.50% | ▲ +3.78% | $1.92 (+4.00%) |
|
May 27, 2026
19d ago
|
EFFECT
| $2.07 $2.08 | ▲ +0.48% | ▼ −0.07% | $1.92 (−7.25%) |
|
May 26, 2026
19d ago
|
6-K
| $2.07 $2.08 | ▲ +0.48% | ▼ −0.06% | $1.92 (−7.25%) |
|
May 22, 2026
23d ago
|
6-K
| $2.13 $2.07 | ▲ +2.82% | ▲ +2.83% | $1.92 (+9.86%) |
|
May 22, 2026
24d ago
|
Press Release
| $2.08 $2.13 | ▼ −2.40% | ▼ −1.82% | $1.92 (+7.69%) |
|
May 21, 2026
24d ago
|
Press Release
| $2.08 $2.13 | ▼ −2.40% | ▼ −1.82% | $1.92 (+7.69%) |
|
May 18, 2026
27d ago
|
6-K
| $3.56 $3.74 | ▲ +5.06% | ▲ +4.02% | $1.92 (−46.07%) |
|
May 18, 2026
27d ago
|
Press Release
| $3.64 $3.56 | ▲ +2.20% | ▲ +1.55% | $1.92 (+47.25%) |
|
Apr 27, 2026
6w ago
|
6-K
| $3.88 $3.75 | ▼ −3.41% | ▼ −3.40% | $1.92 (−50.52%) |
|
Mar 31, 2026
10w ago
|
Press Release
| $3.77 $4.36 | ▲ +15.65% | ▲ +14.90% | $1.92 (−49.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access